Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05283720 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

A Phase 2 study of Non-Hodgkin Lymphoma, sponsored by Genmab.

Recruiting
Registry status
Phase 2
Development phase
496
Enrollment target
20
Study locations

NCT05283720 is a Phase 2 study of Non-Hodgkin Lymphoma that is actively recruiting participants, run by Genmab. The registered enrollment target is 496 participants, above the 147-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (237% higher). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05283720, a Phase 2 study of Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by Genmab.

RECRUITING
Registry status
Phase 2
Development phase
496 participants
Enrollment target
20
Study locations

Study Summary

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and tolerability of epcoritamab in combination with anti-neoplastic agents in adult participants with Non-Hodgkin lymphoma (NHL). Adverse events and change in disease activity will be assessed. Epcoritamab is an investigational drug being developed for the treatment of NHL. Study doctors put the participants in groups called treatment arms. The combination of epcoritamab with anti-neoplastic agents will be explored. Each treatment arm receives a different treatment combination depending on eligibility. Approximately 496 adult participants with NHL will be enrolled in 100 sites globally. In both the dose escalation and dose expansion arms participants will receive subcutaneous (SC) epcoritamab in 28 day, 21 day, or 56 day cycles dependent on the arm in combination with the anti-neoplastic agents described below: 1: Oral lenalidomide in participants (PPTS) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL); 2: Oral ibrutinib and oral lenalidomide in PPTS with R/R DLBCL; 3: Intravenous (IV) polatuzumab vedotin, IV rituximab, IV cyclophosphamide, IV doxorubicin hydrochloride (HCl), and oral prednisone (pola-R-CHP) in PPTS with newly diagnosed treatment-naïve DLBCL, or completion of treatment in 3B; 4: Oral CC-99282 in PPTS with R/R DLBCL; 5: Oral CC-99282 in PPTS with R/R follicular lymphoma (FL); 6A: Oral ibrutinib in PPTS with R/R mantle cell lymphoma (MCL). There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Conditions Studied

Non-Hodgkin Lymphoma

Interventions

  • DRUG Cyclophosphamide
  • DRUG Epcoritamab
  • DRUG Rituximab
  • DRUG Lenalidomide
  • DRUG Ibrutinib

Study Locations (20)

North Carolina

  • Novant Health Presbyterian Medical Center /ID# 242148 - Charlotte
  • East Carolina University - Brody School of Medicine /ID# 242506 - Greenville
  • Novant Health Forsyth Medical Center /ID# 242198 - Winston-Salem

New York

  • Northwell Health - Monter Cancer Center /ID# 245435 - Lake Success
  • Icahn School of Medicine at Mount Sinai /ID# 242123 - New York

Pennsylvania

  • Thomas Jefferson University Hospital /ID# 242077 - Philadelphia
  • Fox Chase Cancer Center /ID# 242106 - Philadelphia

Washington

  • Swedish Medical Center - Seattle /ID# 242269 - Seattle
  • MultiCare Institute for Research & Innovation /ID# 242127 - Tacoma

Arizona

  • The University of Arizona Cancer Center - North Campus /ID# 242219 - Tucson

Connecticut

  • Yale University School of Medicine /ID# 242089 - New Haven

Delaware

  • Christiana Care Health Service /ID# 242301 - Newark

Florida

  • Tampa General Hospital /ID# 246748 - Tampa

Trial Details

FieldValue
Enrollment Target 496 participants
Start Date 2022-06-14
Est. Completion 2032-11
Phase Phase 2

Sponsor

Genmab

45 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05283720

The ClinicalTrials.gov registry entry for NCT05283720 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 496 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 147-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (237% higher). The listed sponsor is Genmab, which has 45 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.

NCT05283720 reports 20 study locations spanning 15 distinct geographic areas - top geographies include North Carolina, New York, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05283720 about?

NCT05283720 is a clinical study titled "A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma". B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and tolerability of epcoritamab in combination with anti-neoplastic agents in adult participants with Non-Hodgkin lymp...

What is the current status of trial NCT05283720?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 496 participants. The study started on 2022-06-14. Estimated completion is 2032-11.

What conditions does trial NCT05283720 study?

This clinical trial studies the following conditions: Non-Hodgkin Lymphoma.

What interventions are being tested in trial NCT05283720?

The interventions under investigation include: Cyclophosphamide (DRUG), Epcoritamab (DRUG), Rituximab (DRUG), Lenalidomide (DRUG), Ibrutinib (DRUG).

Who is sponsoring clinical trial NCT05283720?

This trial is sponsored by Genmab, which has 45 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05283720 being conducted?

This trial has 20 study locations across Arizona, Connecticut, Delaware, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Hodgkin Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Hodgkin Lymphoma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.